<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02741258</url>
  </required_header>
  <id_info>
    <org_study_id>IOSI-INF-001</org_study_id>
    <nct_id>NCT02741258</nct_id>
  </id_info>
  <brief_title>Mepitel Film Treatment for the Prevention and Cutaneous Toxicity Due to Radiotherapy</brief_title>
  <official_title>Mepitel Film vs Standard of Care for the Radiotherapy Prevention and Cutaneous Toxicity in Patients With Post-surgery Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dario Valcarenghi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncology Institute of Southern Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study, mepitel vs standard of care for the prevention and skin toxicity
      due to radiotherapy in patients with post-surgery breast cancer.

      Mepitel film will be placed on the skin of the patients just before the start of the
      radiotherapy and will be replaced once a week until the end of the radiotherapy. In case of
      skin toxicities mepitel film will be placed until resolution of toxicities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients randomized in the mepitel arm:

      Mepitel film will be placed on the patients' skin just before the start of the radiotherapy
      and will be replaced once a week until the end of the radiotherapy. In case of skin
      toxicities mepitel film will be placed until resolution of the toxicities. In case of new
      skin toxicities appearance the patient will be retreated with mepitel.

      For patients randomized in the standard of treatment arm:

      Patients will be treated with aqueous (Excipial U hydrolotion) or antiseptic (Flammazine o
      Ialugen Plus) cream in case of skin erythema. In case of new skin toxicities appearance the
      patient will be retreated with standard of care treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mepitel Film efficacy in treating skin toxicity evaluatet with Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>one week after start of radiotherapy</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) V.4 will be used to evaluate the toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for the skin toxicity appearance and resolution</measure>
    <time_frame>one week after start of radiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of the chronic skin toxicity</measure>
    <time_frame>one week after start of radiotherapy</time_frame>
    <description>Common Terminology Criteria for Adverse Events (CTCAE) v.4</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Post-surgery Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Mepitel Film</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mepitel film will be placed on the patients' skin just before the start of the radiotherapy and will be replaced once a week until the end of the radiotherapy. In case of skin toxicities mepitel film will be placed until resolution of the toxicities. In case of new skin toxicities appearance the patient will be retreated with Mepitel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Excipial U hydrolotion, Flammazin skin cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be treated with aqueous (Excipial U hydrolotion) or antiseptic (Flammazine or Ialugen Plus) cream in case of skin erythema due to radiotherapy. In case of new skin toxicities appearance the patient will be retreated with standard of care treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mepitel Film</intervention_name>
    <description>Placement of Mepitel Film to prevent skin toxicity</description>
    <arm_group_label>Mepitel Film</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>skin cream</intervention_name>
    <description>cream to treat skin erythema due to radiotherapy</description>
    <arm_group_label>Excipial U hydrolotion, Flammazin skin cream</arm_group_label>
    <other_name>Excipial U hydrolotion, Flammazin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with breast cancer treated with conservative surgery

          -  capability and willness to participate to the study

          -  informed consent form signature

        Exclusion Criteria:

          -  contraindication to the correct placement of the Mepitel Film

          -  previous breast radiation treatment

          -  participating in other clinical trials

          -  previous breast reconstruction

          -  concomitant treatment with antiblastic chemotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dario Valcarenghi</last_name>
    <role>Study Chair</role>
    <affiliation>Oncology Institute of Southern Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dario Valcarenghi</last_name>
    <phone>+41918119452</phone>
    <email>dario.valcarenghi@eoc.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laura Moser</last_name>
    <phone>+41918118260</phone>
    <email>laura.moser@eoc.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MariaCarla Valli, Dr.</last_name>
      <phone>+41918119430</phone>
      <email>mariacarla.valli@eoc.ch</email>
    </contact>
    <contact_backup>
      <last_name>Dario Valcarenghi</last_name>
      <phone>+41918119452</phone>
      <email>dario.valcarenghi@eoc.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut für Radiotherapie Klinik Hirslanden</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hansjörg Vees, Dr. med.</last_name>
      <phone>+41 (0)44 387 2550</phone>
      <email>Hansjoerg.Vees@hirslanden.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2016</study_first_posted>
  <last_update_submitted>November 24, 2017</last_update_submitted>
  <last_update_submitted_qc>November 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oncology Institute of Southern Switzerland</investigator_affiliation>
    <investigator_full_name>Dario Valcarenghi</investigator_full_name>
    <investigator_title>Clinical Research Nurse</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>not foreseen</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

